Oncologiedagen 2018: Jos Merkus
Select to filter on program types
Prof. Chris Brightling provides us with a comprehensive summary of the AssesmenT of smalL Airways involvemeNT In aSthma (ATLANTIS), the largest study so far investigating the role of the small airways in asthma.
Maarten van den Berge explains what nasal gene expression profling in small airways dysfunction is all about: what are we talking about exactly? And to what extent can we use it in clinical practice?
Prof. Salman Siddiqui elaborates on the role of radio-imaging, in particular the CT-scan, when trying to better understand small airways dysfunction.
Prof. Klaus Rabe shares his vision on the treatment landscape of asthma and particularly on that of small airways dysfunction.
Em. prof. Dirkje Postma has been involved in research on the small airways for years. This interview offers a brief introduction and summary of the AssesmenT of smalL Airways involvemeNT In aSthma (ATLANTIS).
Dr. Tommaso Sanna (Rome, Italy) shares an overview on the several tools for AF detection after a stroke event. He focuses on the benefits and limitations of the different tools. Dr. Tze-Fan Chao (Taipei, Taiwan) explains how to treat a patient who needs anticoagulants, but who also experiences a intracranial bleeding event previously, using previous results from an ongoing study. Dr. Jeff Healey (Hamilton, Canada) talks about the debate on stroke and bleeding risk scores. Are these tools in everyday clinical practice or not?
The first program of these series presented to you from Cardiostim EHRA Europace 2014 provides an update on stroke prevention and anticoagulation. Prof. dr. Gerhard Hindricks (Leipzig, Germany) provides an update on the current approach when stopping anticoagulation in AF patients might be an option. Prof. dr. Hein J. Heidbüchel (Leuven, Belgium) explains the use of anticoagulation in AF according to the practical guide, which is presented as an addition to the European anticoagulation guidelines. Dr. Robert P. Giugliano (Boston, MA, USA) deals with the results of the ENGAGE AF- TIMI 48 trial. He presents five updated results of subgroup analysis.
This second program from the Cardiostim EHRA Europace 2014 discusses three trials regarding Atrial Fibrillation Prof. dr. Jonathan Halperin (New York, USA) shares the results of the IMPACT trial, which is a multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices. Dr. Michael Orlov (Boston, USA) talkes about the RATE registry trial. The RATE registry is a multicenter observational study of patients with devices followed between 2007 and 2012 in order to evaluate the clinical implications of device detected AT/AF. Dr. Atul Verma (Newmarket, Canada) presents the results of the DISCERN AF trial, looking at the effect of ablation on Asymptomatic Atrial Fibrillation.
Dr. Hugh Calkins (Baltimore, USA) held a state-of-the-art lecture on the knowledge gaps in AF treatment in 80 vs. 60 year-olds. Dr. Yong-Mei Cha (Rochester, MN, USA) presented an example of treatment decisions in a 83 yr-old frail female patient with several comorbidities. Dr. Komandoor Srivathsan (Scottsdale, PH, USA) similarly discussed treatment of AF in a very active 85 year-old surgeon.
Prof. dr. Jean-Yves Le Heuzey elaborates on the evolving landscape for treatment of Atrial Fibrillation in Europe, taking the direct oral anticoagulants into account. Prof. dr. Vincent Thijs (Leuven, Belgium) discusses the relation between stroke and atrial fibrillation in the light of anticoagulation with NOACs. Prof. dr. A. John Camm (London, UK) talks about the association of AF and Stroke. In his talk het emphasizes the use of the new CHADS-VASc score for stroke risk estimation.